Replies to post #239438 on Biotech Values

[DewDiligence]

BCRX acquires ATXS for $8.55 cash/0.59 shares—a package worth ~$12.30 (based on where BCRX is trading today), a 45% premium to yesterday’s closing price:

https://www.globenewswire.com/news-release/2025/10/14/3166038/29446/en/BioCryst-to-Acquire-Astria-Therapeutics-Strengthening-Presence-in-HAE-Transforming-Growth-Profile.html

The nominal deal value is $700M.